8-K: Centene Reports Strong Q3 2024 Results, Reaffirms Full-Year EPS Guidance

Centene Corporation announced its third quarter 2024 financial results, reporting a diluted EPS of $1.36 and adjusted diluted EPS of $1.62, while reaffirming its full-year adjusted diluted EPS guidance.

Summary

• Centene Corporation reported total revenues of $42.023 billion and premium and service revenues of $36.899 billion for the third quarter of 2024.
• The company's diluted earnings per share (EPS) was $1.36, and adjusted diluted EPS was $1.62.
• Centene saw a 22% increase in Marketplace membership and a 49% increase in Medicare Prescription Drug Plan (PDP) membership compared to the third quarter of 2023.
• The company executed $1.2 billion in share repurchases during the third quarter and an additional $380 million in October, bringing the total to $2.4 billion through October 2024.
• Centene reaffirmed its 2024 adjusted diluted EPS guidance floor of greater than $6.80.
• The health benefits ratio (HBR) was 89.2%, an increase from 87.0% in the same period last year, driven by higher acuity in Medicaid and Medicare Star rating impacts.
• The company's SG&A expense ratio was 8.3%, down from 8.7% in the third quarter of 2023, due to divestitures and leveraging of expenses.
• Cash flow used in operations was $1.0 billion, primarily due to the settlement of Marketplace risk adjustment payables and Medicaid rate increases not yet collected.
• Centene had $36.7 billion in cash, investments, and restricted deposits at the end of the quarter.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong membership growth and reaffirmed guidance, but there are some concerns about increased medical costs and cash flow.

Positives

• Centene's diversified portfolio allowed it to navigate a dynamic landscape successfully.
• The company delivered on fundamentals that carry positive implications for its multi-year earnings trajectory.
• Centene achieved notable RFP wins, Medicare Stars improvements, and ongoing operational efficiencies.
• The company is well-positioned to capture long-term growth opportunities in government-sponsored healthcare.
• Centene's Medicare Advantage Star Ratings improved significantly, with 46% of members in plans rated 3.5 stars or higher.
• The company secured several new contracts, including a significant dual-eligible plan in Michigan.
• Centene was recognized by Fortune magazine as one of the Best Workplaces in Health Care 2024 for the third consecutive year.
• The company's share repurchase program demonstrates a commitment to returning value to shareholders.

Negatives

• Cash flow used in operations was $1.0 billion for the third quarter of 2024.
• The health benefits ratio (HBR) increased to 89.2%, driven by higher acuity in Medicaid and Medicare Star rating impacts.
• Medicaid membership decreased due to redeterminations and recent divestitures.
• The company experienced a decrease in days in claims payable by three days compared to the second quarter of 2024.

Risks

• The company faces risks related to Medicaid redeterminations, which have led to lower membership.
• Fluctuations in medical utilization rates could impact the company's financial performance.
• Competition for providers, broker distribution networks, and contract reprocurements could pose challenges.
• The company's ability to manage information systems effectively is crucial for maintaining service levels.
• Changes in healthcare practices, new technologies, and advances in medicine could impact the business.
• The company is subject to risks related to government shutdowns, debt ceilings, and funding.
• Legal or regulatory audits, investigations, and proceedings could impact the company's operations.
• Cyber-attacks or other data security incidents could pose a threat to the company's data and operations.

Future Outlook

Centene is updating its 2024 GAAP diluted EPS guidance floor to greater than $5.92 and reaffirming its 2024 adjusted diluted EPS guidance floor of greater than $6.80. The company is confident in its long-term growth opportunities in government-sponsored healthcare.

Management Comments

• Our diversified portfolio has allowed us to successfully navigate a dynamic landscape in the quarter.
• We delivered on fundamentals that carry positive implications for Centene's multi-year earnings trajectory, including notable RFP wins, Medicare Stars improvements and ongoing operational efficiencies.
• We remain confident in our full year outlook for adjusted diluted EPS of greater than $6.80 and are well positioned to capture the powerful, long-term growth opportunities we see in government-sponsored healthcare.

Industry Context

This announcement comes as the healthcare industry continues to navigate changes in government regulations and market dynamics. Centene's focus on government-sponsored programs and its ability to secure new contracts positions it well within the current landscape. The company's improved Medicare Star ratings are also a positive sign in a competitive market.

Comparison to Industry Standards

• Centene's adjusted diluted EPS of $1.62 is comparable to other large managed care organizations such as UnitedHealth Group (UNH) and Humana (HUM), although specific comparisons would require a detailed analysis of their respective Q3 results.
• The 22% increase in Marketplace membership is a strong performance, indicating successful product positioning and market growth, which is a key metric for companies in this sector.
• The 49% increase in Medicare PDP membership is also notable, suggesting Centene is effectively capturing market share in this segment, which is a key growth area for many healthcare companies.
• Centene's improvement in Medicare Star ratings, with 46% of members in plans rated 3.5 stars or higher, is a significant achievement compared to the previous year's 23%, and is a key indicator of quality and member satisfaction, which is a focus for all companies in the sector.
• The company's health benefits ratio (HBR) of 89.2% is within the expected range for managed care companies, although the increase from 87.0% in the prior year indicates higher medical costs, which is a trend being seen across the industry.
• The SG&A expense ratio of 8.3% is a positive sign of cost management, especially given the growth in the Marketplace business, which typically has higher SG&A expenses.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and reaffirmed EPS guidance.
• Employees will benefit from the company's recognition as a top workplace.
• Members will benefit from improved Medicare Star ratings and access to new programs.
• Providers will benefit from new contracts and partnerships.
• Communities will benefit from Centene's community engagement and support initiatives.

Next Steps

• The company will host a conference call on October 25, 2024, to discuss the financial results.
• Centene will continue to execute its share repurchase program.
• The company will focus on implementing new contracts and improving Medicare Star ratings.
• Centene will continue to monitor and manage the impact of Medicaid redeterminations.

Key Dates

Keywords

Healthcare, Managed Care, Medicaid, Medicare, Health Insurance, EPS, Membership, Share Repurchase, Star Ratings, Government Programs